Loading...
XSHE
002773
Market cap3.04bUSD
Jul 10, Last price  
22.31CNY
1D
1.97%
1Q
-20.46%
Jan 2017
-48.93%
IPO
101.69%
Name

Chengdu Kanghong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002773 chart
P/E
17.67
P/S
4.48
EPS
1.26
Div Yield, %
2.69%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
6.83%
Revenues
4.59b
+2.98%
638,209,500796,088,0001,016,532,6001,331,374,4001,476,627,5001,674,518,5402,074,352,0612,540,031,5212,786,496,9992,917,445,1313,257,430,0973,295,430,1193,605,346,5523,389,028,1583,957,459,6414,452,657,7984,585,133,789
Net income
1.16b
-2.37%
82,447,200108,507,000165,026,400202,745,600315,712,900273,481,712393,813,317496,751,947644,199,035694,943,804718,190,270-269,853,091421,084,377896,670,0361,044,765,7621,191,230,7611,162,966,864
CFO
1.50b
+6.50%
108,422,900136,794,400168,858,000281,838,851333,314,772291,375,787481,971,711846,345,107766,862,498350,884,404812,145,677273,315,485494,114,176925,153,3841,218,411,1261,411,874,8371,503,648,452
Dividend
Jun 06, 20250.6 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chengdu Kanghong Pharmaceuticals Group Co., Ltd operates within China, focusing on the research, development, production, and marketing of a wide array of pharmaceutical goods. These include biologics, traditional Chinese medicines, and chemical drugs. The company's offerings span treatments for ophthalmic ailments, central nervous system conditions, digestive disorders, and other therapeutic areas. Founded in 1996, its corporate headquarters are located in Chengdu, China.
IPO date
Jun 26, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT